OBJECTIVES: Recent evidence suggests that the presence of a systemic inflammatory response plays an important role in the progression of several solid tumors.
The platelet-to-lymphocyte ratio (PLR) has been proposed as an easily assessable marker of systemic inflammation and has been shown to represent a prognostic marker in different cancer entities. To evaluate the prognostic value of the PLR in prostate cancer, we performed the present study.
METHODS AND MATERIALS: Data from 374 consecutive patients with prostate cancer, treated with 3D conformal radiotherapy from 1999 to 2007, were analyzed. Distant metastases-free survival (MFS), cancer-specific survival (CSS), overall survival (OS), biochemical disease-free survival, and time to salvage systemic therapy were assessed using the Kaplan-Meier method. Cox proportional hazards analysis was performed to calculate hazard ratio (HR) and 95% CI. Multivariate Cox regression analysis was performed to adjust for other covariates.
RESULTS: Using receiver operating characteristics analysis, the optimal cutoff level for the PLR was 190. Kaplan-Meier analyses revealed that PLR ≥190 was a prognostic factor for decreased MFS (P = 0.004), CSS (P = 0.004), and OS (P = 0.024) whereas a significant association of an elevated PLR with biochemical disease-free survival (P = 0.740) and time to salvage systemic therapy (P = 0.063) was not detected. In multivariate analysis, an increased PLR remained a significant prognostic factor for poor MFS (HR = 2.24, 95% CI: 1.06-4.76, P = 0.036), CSS (HR = 3.99, 95% CI: 1.19-13.4, P = 0.025), and OS (HR = 1.87, 95% CI: 1.02-3.42, P = 0.044).
CONCLUSIONS: Our findings indicate that the PLR may predict prognosis in patients with prostate cancer and may contribute to future individual risk assessment in them.
Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger A, Langsenlehner U. Are you the author?
Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center, Medical University of Graz, Austria; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, TX; Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria; Department of Medicine, Comprehensive Cancer Center, Medical University of Graz, Austria; Division of Internal Medicine, Outpatient Department Graz, Austria.
Reference: Urol Oncol. 2015 Mar 10. pii: S1078-1439(15)00062-9.